FDA issues bismacine-chromacine warning

Jul 24, 2006

The U.S. Food and Drug Administration is warning consumers and healthcare providers not to use a product called bismacine, also known as chromacine.

The FDA says it is investigating one report of a death and several reports of injury related to the administration of bismacine -- an injectable product that has been used to treat Lyme disease.

FDA officials said bismacine, which is not approved for anything, including Lyme disease, is not a pharmaceutical and is mixed individually by druggists. It is prescribed or administered by doctors of "alternative health" or by people claiming to be medical doctors.

The product contains high amounts of bismuth, a heavy metal that is used in some medications to treat Helicobacter pylori, a bacteria that can cause stomach ulcers but that is not approved in any form for use by injection.

Copyright 2006 by United Press International

Explore further: Unidentified fever kills 13 in DR Congo in 10 days

add to favorites email to friend print save as pdf

Related Stories

Google buys travel guide app startup Jetpac

2 hours ago

Google confirmed Monday it has bought the startup behind a Jetpac mobile application that creates insightful travel guides by analyzing pictures from social networks such as Instagram.

Sharp Aquos Crystal phone: Where's the bezel?

2 hours ago

Just when you thought a fashionable gadget must be somewhat thin, Sharp is going to charm the smartphone fashion-conscious with a crazily thin phone, and it is arriving in the US quite soon. Gorgeous. Cool. ...

Recommended for you

Obama offers new accommodations on birth control

52 minutes ago

The Obama administration will offer a new accommodation to religious nonprofits that object to covering birth control for their employees. The measure allows those groups to notify the government, rather than their insurance ...

Towards renal artery stenosis treatment

1 hour ago

Renal artery stenting to open blockages in the kidney arteries may benefit patients who have historically been excluded from modern clinical trials, according to new recommendations for renal artery stenosis e-published in ...

User comments : 0